Clinical Trial Update: Unacylated Ghrelin to Improve Functioning in PAD [Phase 2]

View source ↗

Summary

Northwestern University conducted a Phase 2 trial of unacylated ghrelin for improving functioning in peripheral artery disease; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Drugs mentioned

• Unacylated Ghrelin (unacylated ghrelin)

Snippet

Sponsor: Northwestern University | Conditions: Peripheral Artery Disease | Phase 2 | Status: COMPLETED